@article {7908,
	title = {Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group},
	journal = {Lung Cancer},
	volume = {58},
	year = {2007},
	note = {Cited By :10Export Date: 21 February 2017},
	month = {2007},
	pages = {355 - 361},
	abstract = {Objective: The purpose of this study was to evaluate the efficacy and toxicity of cisplatin, etoposide and irinotecan as first-line treatment in patients with extensive small-cell lung cancer (E-SCLC). Patients and methods: Chemo-na{\"\i}ve adult patients with a performance status (PS) of 0-2 and adequate organ function were eligible. Patients received cisplatin 20 mg/m2 i.v. daily for three consecutive days, etoposide 75 mg/m2 i.v. daily for three consecutive days and irinotecan 120 mg/m2 i.v. on day 2, every 21 days for six to eight cycles. Administration of G-CSF was given in the presence of febrile neutropenia and as a 5-day prophylaxis around the recorded nadir day in patients who developed grades 3-4 neutropenia. Results: Fifty-six patients were assessable. The median age was 62.2 years; 96.4\% had PS 0-1, 33.5\% had \&gt;3 metastatic sites. The overall response rate was 80.4\% with 8 (14.3\%) patients achieving a complete response. The median time to tumor progression was 7.8 months [95\% confidence interval (CI), 7.1-8.6 months] with a median survival of 15.1 months [95\% CI, 9.7-20.5 months] and 1-year survival rate of 56.5\%. One patient died from toxicity. Grades 3-4 neutropenia occurred in 37.5\% of patients, grades 3-4 thrombocytopenia occurred in 10.9\% of patients and 11 (19.6\%) patients developed febrile neutropenia. Grades 3-4 non-hematological toxicities were primarily nausea-vomiting 3.6\%, diarrhea 7.1\% and fatigue 3.6\%. Conclusion: This study strongly suggests that cisplatin, etoposide and irinotecan combination is very effective for the treatment of E-SCLC with good safety profile. The triplet regimen currently seems a promising regimen and has to be further explored in phase III trials. {\textcopyright} 2007 Elsevier Ireland Ltd. All rights reserved.},
	keywords = {Cisplatin, Etoposide, Extensive small-cell lung cancer, Irinotecan},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-35748983543\&doi=10.1016\%2fj.lungcan.2007.06.027\&partnerID=40\&md5=8594ed1671d8c32ce048f40d71cee9de},
	author = {Pectasides, D. and Samantas, E. and Fountzilas, G. and Briasoulis, E. and Kosmidis, P. and Skarlos, D. and Dimopoulos, M.A. and Kalofonos, H.P. and Economopoulos, T. and Syrigos, K.}
}
